In 2004, we previously identified a prominent mimotope (VPELGHE) of autoantibodies in ovarian cancer patients with phage display‐based “fingerprinting.” With the benefit of more than two decades of biomedical literature and open‐access data, we have re‐explored this mimotope with a computational workflow and defined a previously unrecognized region of matrix metalloproteinase 14 (MMP14) and other MMPs as a promising epitope for theranostic applications in ovarian cancer and potentially other malignancies. This evidence concerns the gene MMP14 and ovarian cancer.